Abby Hardy, Author at BioTuesdays

Feature

NanoViricides targeting multiple types of viral infection with nanomedicine platform

Using its nanomedicine platform and the capabilities of its cGMP manufacturing facility, NanoViricides (NYSE American: NNVC) is developing therapeutics for a variety of viral infections, including herpes simplex viruses...

April 14, 2020

Developments

Bellerophon submits IND for INOpulse inhaled nitric oxide for COVID-19

Bellerophon Therapeutics (NASDAQ:BLPH) submitted an IND to the FDA to study INOpulse, a pulsed nitric oxide (NO) system, for the treatment of patients with COVID-19. The IND follows the FDA’s allowance of treatment with...

April 9, 2020

Developments

MEI Pharma gets FDA fast track designation for follicular lymphoma

MEI Pharma’s (NASDAQ:MEIP) ME-401 received FDA fast track designation for the treatment of patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies. The company is...

March 31, 2020

Feature

Amidst a global pandemic, two biotech companies offer innovative solutions

Since COVID-19 was first identified in China late last year, researchers have been working tirelessly to develop diagnostics, therapeutics and vaccines in an effort to prevent the spread of the SARS-CoV-2 virus. Many...

March 31, 2020

Developments

Profound Medical’s TULSA-PRO now available at Georgia’s renowned Busch Center

Georgia’s renowned Busch Center is now offering Profound Medical’s (NASDAQ:PROF; TSX:PRN) TULSA-PRO procedure to treat unhealthy prostate tissue. The technology, which was cleared by the FDA in August 2019, provides...

March 26, 2020

Developments

Prevail Therapeutics gets FDA fast track designation for frontotemporal dementia gene therapy

Prevail Therapeutics (NASDAQ:PRVL) received FDA fast track designation for PR006, a gene therapy candidate designed to slow the progression of frontotemporal dementia with a GRN mutation. Frontotemporal dementia is the...

March 24, 2020

Executive Moves

Akcea names Damien Devitt as CEO

Damien Devitt, who has been interim CEO of Akcea Therapeutics (NASDAQ:AKCA) since September 2019, has been promoted to CEO, effective immediately, and will continue to serve as a member of Akcea’s board. “With his...

March 24, 2020

Markets

Mackie Research ups Profound Medical to speculative buy

Mackie Research upgraded Profound Medical (TSX:PRN; NASDAQ:PROF) to “speculative buy” from “hold,” but reduced its price target to $16.20 from $26.10 due to the anticipated impact of the coronavirus. The stock closed at...

March 24, 2020

Markets

Analysts see strong rationale for Hepion CRV431’s use in severe COVID-19 cases

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431, a cyclophilin inhibitor with antifibrotic and antiviral properties, may show some effect in the ongoing COVID-19 pandemic, according to Roth Capital Partners and Brookline...

March 20, 2020

Developments

Dicerna gets FDA orphan drug designation for alpha-1 antitrypsin deficiency drug candidate

Dicerna Pharma (NASDAQ:DRNA) received FDA orphan drug designation for DCR-A1AT for the treatment of alpha-1 antitrypsin deficiency, a genetic disorder that can cause lung and liver disease. The company submitted a...

March 19, 2020

Author - Abby Hardy

NanoViricides targeting multiple types of viral infection with nanomedicine platform

Bellerophon submits IND for INOpulse inhaled nitric oxide for COVID-19

MEI Pharma gets FDA fast track designation for follicular lymphoma

Amidst a global pandemic, two biotech companies offer innovative solutions

Profound Medical’s TULSA-PRO now available at Georgia’s renowned Busch Center

Prevail Therapeutics gets FDA fast track designation for frontotemporal dementia gene therapy

Akcea names Damien Devitt as CEO

Mackie Research ups Profound Medical to speculative buy

Analysts see strong rationale for Hepion CRV431’s use in severe COVID-19 cases

Dicerna gets FDA orphan drug designation for alpha-1 antitrypsin deficiency drug candidate

Subscribe